Journal
EJHaem
Publication Date
2-1-2024
Volume
5
Issue
1
First Page
105
Last Page
116
Document Type
Open Access Publication
DOI
10.1002/jha2.854
Rights and Permissions
Oh ST, Verstovsek S, Gupta V, Platzbecker U, Devos T, Kiladjian JJ, McLornan DP, Perkins A, Fox ML, McMullin MF, Mead AJ, Egyed M, Mayer J, Sacha T, Kawashima J, Huang M, Strouse B, Mesa R. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis. EJHaem. 2024 Feb 5;5(1):105-116. doi: 10.1002/jha2.854. Erratum in: EJHaem. 2024 May 24;5(3):646. doi: 10.1002/jha2.934. © 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Recommended Citation
Oh, Stephen T and et al., "Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis." EJHaem. 5, 1. 105 - 116. (2024).
https://digitalcommons.wustl.edu/oa_4/4388
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
